Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)

Seminars in Oncology

Volumn 26, Issue 4 SUPPL. 12, 1999, Pages 60-70

  Sliwkowski, M X ^a   Lofgren, J A ^a   Lewis, G D ^a   Hotaling, T E ^a   Fendly, B M ^a   Fox, J A ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL CYCLE S PHASE; COMPLEMENT DEPENDENT CYTOTOXICITY; DNA DAMAGE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN FAMILY; RECEPTOR DOWN REGULATION; TARGET CELL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMPLEMENT ACTIVATION; DOWN-REGULATION; HUMANS; NEOPLASMS; RECEPTOR, ERBB-2;

EID: 0032851961     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)